Profund Advisors LLC Has $1.73 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Profund Advisors LLC increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 48.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 22,240 shares of the company’s stock after buying an additional 7,227 shares during the quarter. Profund Advisors LLC’s holdings in Kymera Therapeutics were worth $1,730,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. US Bancorp DE increased its position in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 9.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after purchasing an additional 248 shares in the last quarter. Larson Financial Group LLC increased its position in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in Kymera Therapeutics by 2.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock worth $2,379,000 after purchasing an additional 645 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Kymera Therapeutics by 5.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company’s stock valued at $1,216,000 after acquiring an additional 789 shares during the period.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 91,250 shares of the firm’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $77.41, for a total value of $7,063,662.50. Following the transaction, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $4,737,646.82. This trade represents a 59.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,576 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $88.93, for a total transaction of $673,733.68. Following the completion of the transaction, the chief financial officer directly owned 237,483 shares in the company, valued at $21,119,363.19. This trade represents a 3.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 383,734 shares of company stock valued at $32,454,902. Corporate insiders own 15.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on KYMR. Stephens upped their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Royal Bank Of Canada restated an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Citigroup upped their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Canaccord Genuity Group began coverage on shares of Kymera Therapeutics in a research report on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.10.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $80.65 on Thursday. The firm’s fifty day moving average is $83.31 and its 200-day moving average is $78.44. Kymera Therapeutics, Inc. has a 52 week low of $28.06 and a 52 week high of $103.00. The firm has a market cap of $6.63 billion, a P/E ratio of -22.59 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same period in the prior year, the firm posted ($0.82) EPS. The company’s quarterly revenue was up 55.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.